Healthcare Systems Explained: Japan

Japan has achieved something few healthcare systems in the world can claim: near-universal coverage, among the lowest infant mortality rates globally, and the highest average life expectancy of any large country — all while spending significantly less per capita than the United States. The system that produces these outcomes is structurally different from both European statutory models and US insurance markets in ways that matter when translating Japanese medical records for international use.

Universal Coverage Through Two Parallel Systems

Japan’s universal health insurance (Kokumin Kaiho — National Health Insurance) is not a single-payer system. It operates through two parallel tracks that cover virtually the entire population:

1. Shakai Hoken (Employment-Based Insurance) Workers at medium and large employers are enrolled in employer-sponsored health insurance managed by Japan Health Insurance Association (Kyokai Kenpo) or large-employer-specific funds (Kenpo Kumiai). Employees pay roughly 50% of the premium, employers pay 50%. Coverage extends to dependents.

2. Kokumin Kenko Hoken (National Health Insurance, NHI) Self-employed workers, retirees not yet covered by employee insurance, freelancers, and those in smaller workplaces enroll in NHI, managed at the municipality level. NHI premiums are income-based and paid directly by the insured.

Both tracks provide the same legally mandated benefit package. A patient’s insurance track affects their premium, not their covered benefits. At age 75, nearly all Japanese residents transition to the Koki Koreisha Iryo Seido (Later-Stage Elderly Medical Care System), a separate insurance program with subsidized premiums and reduced co-pays.

Co-payment structure: Under both tracks, the standard patient co-pay is 30% of the fee schedule price — meaning 70% is covered by insurance. This drops to 20% for children under school age, 20% for those aged 70-74, and 10% for those 75 and older. For high-cost procedures, a monthly cap (Kogen Ryoyo-Hi) limits total patient out-of-pocket spending regardless of treatment cost.

J-ICD: Japan’s Diagnosis Coding Approach

Japan uses a national diagnosis coding system based on ICD-10, but the implementation differs from both the US ICD-10-CM and European national modifications in important ways.

Japan’s medical information standardization effort is coordinated through the Ministry of Health, Labour and Welfare (MHLW) and the Japan Medical Informatics Association. The Standard Disease Name Master (標準病名マスター) is the key reference — a mapping between Japanese disease names (in Japanese text) and corresponding ICD-10 codes.

Practical implications for record translation:

1. Code structure is WHO ICD-10 compatible. Japanese ICD-10 codes follow the WHO 4-digit structure without the deep modifications found in Germany’s GM or the US’s CM. A code like I21.0 (acute transmural myocardial infarction of anterior wall) in a Japanese record corresponds closely to the WHO base, which in turn maps fairly directly to ICD-10-CM I21.09 (ST elevation myocardial infarction involving other coronary artery of anterior wall).

2. Diagnoses are often documented in Japanese text, with ICD codes added for administrative purposes. Unlike German GKV records where ICD coding is deeply embedded in the billing workflow, Japanese outpatient records frequently include free-text Japanese disease names as the primary documentation, with ICD codes appended administratively. This means the ICD code may be less granular than the clinical narrative.

3. Procedure coding uses K-codes. Japan’s procedure coding for billing is based on a national fee schedule using “K-codes” for surgical procedures — a separate system from ICD-10-CM/PCS or OPS. K-codes are defined in the Shinryo Hoshu Tensu Hyo (Medical Fee Schedule), updated every two years. For cross-border clinical record use, K-code procedures typically need to be interpreted from the procedure description rather than mapped numerically.

Kampo: Traditional Medicine in the Modern System

One of the most distinctive features of Japanese healthcare from an international perspective is the full integration of Kampo (漢方, Sino-Japanese herbal medicine) into the national insurance system.

Kampo is a Japanese adaptation of traditional Chinese medicine, formalized and standardized over centuries of practice in Japan. Unlike in many countries where traditional medicine exists outside mainstream healthcare, Japan’s MHLW has approved 148 Kampo formulas for insurance reimbursement under the national fee schedule. These are industrially manufactured extracts (granules or tablets) from licensed manufacturers, with standardized formulations and approved dosage forms.

Why this matters for international record translation:

Kampo treatments appear in Japanese medical records using their Japanese formula names — and these names have no ICD-10 code equivalent and no direct US pharmaceutical equivalent.

Examples:

• Kakkonto (葛根湯, Pueraria Combination): Used for cold/flu onset, stiff neck, mild fever. No FDA-approved pharmaceutical equivalent.
• Daikenchuto (大建中湯): Commonly prescribed post-surgery for bowel motility; subject of clinical trials in the US and Japan for its effects on intestinal function.
• Hochuekkito (補中益気湯): Used for general fatigue, post-illness recovery, immune support.
• Goreisan (五苓散): Used for fluid retention, headache, edema. No single-molecule equivalent.

A post-operative Japanese discharge summary may show a Kampo prescription alongside conventional analgesics and antibiotics. US providers receiving this record should understand these as evidence-based, physician-prescribed traditional medicines — not herbal supplements self-chosen by the patient — that carry their own interaction profiles and clinical context.

Kampo formulas can interact with conventional drugs. Licorice root (glycyrrhizin, found in many Kampo formulas including Shokanzakoto and Tsumuraho) can affect potassium levels and interact with diuretics. Ginger and Aconite-containing formulas have cardiovascular effects relevant to cardiac medication management.

Medical Record Practices

Japan’s medical record-keeping culture has historically been paper-heavy, with individual physicians and hospitals maintaining their own records rather than contributing to shared national repositories. This is changing — the MHLW has accelerated electronic health record (EHR) adoption, and the My Health Record (マイナ保険証) system linking insurance cards to medical records is in active rollout.

However, for records generated before 2023 or from smaller outpatient clinics, several documentation characteristics are common:

Written in Japanese. This seems obvious but has practical implications: Japanese medical records do not follow a standardized document structure enforced by billing systems the way US hospital records do. The format, abbreviations, and clinical shorthand vary by institution and physician.

Kanji-heavy diagnosis documentation. Japanese disease names are often written in Kanji compound terms that carry clinical meaning — 心筋梗塞 (Shinkin Kosoku, myocardial infarction), 糖尿病 (Tounyoubyou, diabetes mellitus), 高血圧 (Kouketsuatsu, hypertension). Accurate translation requires medical Japanese literacy, not general Japanese language ability.

Radiology and lab values in mixed notation. Japanese lab reports use SI units consistently (mmol/L for glucose, g/dL for hemoglobin), consistent with international standards but different from US convention for some values. Blood glucose is reported in mg/dL in the US; Japanese reports may use mmol/L, requiring unit conversion (divide by 18 for glucose).

PMDA vs FDA: Drug Approval Differences

The Pharmaceuticals and Medical Devices Agency (PMDA) is Japan’s drug regulatory authority, roughly analogous to the US FDA. Several categories of drug approval differences affect cross-border record interpretation:

Drugs Approved in Japan But Not the US

Japan has approved several drugs that have not received FDA approval or are indicated for different uses:

• Fasudil (Rho-kinase inhibitor): Approved in Japan for cerebral vasospasm after subarachnoid hemorrhage. Not FDA-approved; used in clinical research in the US.
• Edaravone (Radicut): First approved in Japan for acute ischemic stroke in 2001. The FDA approved edaravone for ALS (as Radicava) in 2017, but the indications differ — a Japanese stroke patient prescribed edaravone is receiving it for a different approved indication than a US ALS patient.
• Various Kampo formulas: The 148 NHI-approved Kampo formulas are not individually FDA-approved drugs (some ingredients have GRAS status, but the formulations as such are not FDA-approved pharmaceuticals).

Drugs Approved in the US But Restricted or Different in Japan

• Direct-to-consumer advertising: Banned in Japan. Drug awareness among Japanese patients comes through physicians, not DTC advertising — prescription rates for brand-name drugs vs. generics reflect this.
• Generic drug adoption: Japan has historically had lower generic substitution rates than the US, partly due to cultural preference for brand-name drugs and partly due to historical reimbursement structures. This is changing under MHLW policy, but a Japanese prescription record may show a brand-name drug where a US equivalent would typically show a generic.
• Dosing differences: Some drugs have different standard doses in Japan vs. the US, reflecting Japanese clinical trials conducted in Japanese patient populations. Warfarin dosing in Japanese patients, for example, tends to be lower than in Western populations due to CYP2C9 and VKORC1 polymorphism frequency differences. A Japanese prescription for warfarin 1-2mg/day is not necessarily undertreated — it may be the appropriate pharmacogenomically-guided dose for that patient.

Drug Name Conventions

Japan uses both the INN (International Nonproprietary Name) in Katakana transliteration and Japanese brand names. Examples:

Japanese Brand	INN	US Common Name
アスピリン (Aspirin)	Acetylsalicylic acid	Aspirin
バイアスピリン	Acetylsalicylic acid (low-dose)	Bayer Aspirin (81mg)
ランソプラゾール	Lansoprazole	Prevacid
オメプラゾール	Omeprazole	Prilosec
アムロジピン	Amlodipine	Norvasc
リバーロキサバン	Rivaroxaban	Xarelto

Drug names in Japanese records appear in Katakana (the script used for foreign loan words) or Kanji. The Katakana transliteration of an INN is the most reliable identifier — Katakana drug names map predictably to INN names.

Health Insurance Card and Patient Identification

Japanese patients carry a Kenko Hoken Sho (健康保険証, health insurance card) or, increasingly, the new My Number Card (マイナンバーカード) with insurance information embedded. These cards identify the insurance type, insurer, policy number, and coverage period.

For cross-border contexts, the insurance type is the key clinical documentation piece — it identifies whether records should be expected to have standardized ICD coding (more likely for hospital inpatient records billing DPC, Japan’s DRG-like system) or less structured outpatient documentation.

How TranslateMD Helps

Cross-border Japanese medical records present a distinct challenge: the combination of WHO-compatible ICD coding, embedded Kampo prescriptions, Japanese-language clinical narrative, and PMDA-specific drug approvals requires more than language translation.

TranslateMD’s Japan support includes:

• Kampo formula recognition and clinical annotation: Identifying Kampo prescriptions from Japanese formula names, providing the formula composition, common clinical use, and known drug interaction profiles — so US providers understand what the patient was receiving and why
• J-ICD to ICD-10-CM mapping: With particular attention to cases where Japanese WHO-base codes are more or less granular than the CM equivalent
• Drug name normalization: Katakana drug names → INN → US equivalent, with PMDA/FDA approval status comparison where relevant
• Dosing range context: For drugs like warfarin where standard dosing may differ between Japanese and Western populations, annotating context for the receiving clinician
• Lab value unit conversion: Handling mmol/L ↔ mg/dL and other Japanese/US unit differences for key lab values

---

Translating Japanese patient records? See TranslateMD’s JP-US corridor documentation or get started with the API.